NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist

Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including treatments for Alzheimer’s and Parkinson’s disease. Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair. With expertise in enhancing patient care and research experience with the Department of Veterans Affairs, he will focus on ensuring the scientific rigor and success of Annovis’ clinical trials for its lead drug candidate, buntanetap.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer